selegiline has been researched along with Disease Models, Animal in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.90) | 18.7374 |
| 1990's | 13 (18.84) | 18.2507 |
| 2000's | 23 (33.33) | 29.6817 |
| 2010's | 24 (34.78) | 24.3611 |
| 2020's | 7 (10.14) | 2.80 |
| Authors | Studies |
|---|---|
| Amar, M; Ferrié, L; Figadère, B; Harfouche, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Séon-Méniel, B; Sepulveda-Diaz, JE | 1 |
| Bahn, YS; Choi, JW; Han, G; Jang, BK; Kim, HJ; Kim, S; Lee, YR; Lee, YS; Pae, AN; Park, JH; Park, KD; Shin, SJ; Yeon, SK | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Guo, K; Jin, M; Li, L; Liu, D; Luo, N; Rong, H; Wang, J; Zhang, J; Zhang, X; Zhang, Y | 1 |
| Abdanipour, A; Anarkooli, IJ; Mirzaei, M; Mohammadi, P | 1 |
| Han, Y; Huang, S; Liu, K; Liu, S; Xiong, F | 1 |
| Baghy, K; Knoll, J; Mervai, Z; Miklya, I; Timar, J; Zelena, D | 1 |
| Gómez-Galán, M; Henning, L; Lindskog, M; Srivastava, I; Vazquez-Juarez, E | 1 |
| Farkas, J; Gáborján, A; Humli, V; Köles, L; Miklya, I; Polony, G; Szepesy, J; Szirmai, Á; Tábi, T; Tamás, L; Tímár, J; Vizi, ES; Zelles, T | 1 |
| Aversa, D; Berretta, N; Cavallucci, V; Coccurello, R; Cordella, A; Cutuli, D; D'Amelio, M; De Bartolo, P; Dell'Acqua, MC; Federici, M; Giacovazzo, G; Keller, F; Krashia, P; Latagliata, EC; Marino, R; Mercuri, NB; Nobili, A; Petrosini, L; Puglisi-Allegra, S; Rizzo, FR; Sancandi, M; Viscomi, MT | 1 |
| Khalifa, AE; Tadros, MG; Wahdan, SA | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Al-Salem, A; Hussain, AM; Kayali, NM; Khan, KM; Rao, MS; Renno, WM; Sadek, HL | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Ali, J; Baboota, S; Dang, S; Kumar, S; Nigam, K | 1 |
| Bajaj, A; Gaud, R; Sridhar, V; Wairkar, S | 1 |
| Abdollahi, A; Akbarfakhrabadi, A; Amiri, S; Behnoush, B; Dehpour, AR; Hosseini, MJ; Javadian, N; Maleki, A; Rahimi, N | 1 |
| Bellinger, DL; Felten, DL; Gridley, DS; Molinaro, CA; ThyagaRajan, S; Tran, L | 1 |
| Bai, Y; Cai, D; Zhao, Q | 1 |
| da Cunha, C; Ferreira, AP; Ferreira, J; Gomes, GM; Mello, CF; Pazini, AM; Pinheiro, F; Rubin, MA; Villarinho, JG | 1 |
| Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Chen, SJ; Huang, HC; Jhang, JG; Ka, SM; Liaw, WJ; Tsao, CM; Wu, CC; Wu, TC | 1 |
| Dobolyi, A; Lakatos, K; Merkely, B; Nagy, Z; Nardai, S; Pál, G; Pintér, N; Skopál, J | 1 |
| Hallan, SS; Mehra, NK; Mishra, N; Prakash, A; Rashid, M; Singh, D | 1 |
| Cheng, X; Li, S; Liu, B; Lv, C; Ma, Y; Mao, W; Sun, J; Zhang, J | 1 |
| Alijanpour, S; Amini-Khoei, H; Amiri, S; Haj-Mirzaian, A; Mehdizadeh, M; Mohammadi-Asl, A; Olson, CO; Rahimi-Balaei, M; Rastegar, M; Razmi, A; Zarrindast, MR | 1 |
| Henn, FA; Huston, JP; Petri, D; Schulz, D | 1 |
| Cheng, X; Li, S; Liu, B; Liu, Y; Lv, C; Ma, Y; Mao, W; Sun, J; Zhang, J | 1 |
| Cohen, S; Dror, V; Eliash, S; Rehavi, M | 1 |
| Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB | 1 |
| Adler, I; Bekesi, G; Dinya, E; Lengyel, G; Magyar, K; Marczell, I; Nagy-Repas, P; Racz, K; Schaff, Z; Stark, J; Szombath, D; Tulassay, Z | 1 |
| Cabreira, TN; Ferreira, J; Oliveira, SM; Silva, CR; Villarinho, JG | 1 |
| Iida, Y; Ogawa, M; Saji, H; Shimazu, S; Takahata, K; Yoneda, F | 1 |
| Iida, Y; Saji, H; Shimazu, S; Takahata, K; Tamashiro, A; Yoneda, F | 1 |
| Endo, T; Hamaue, N; Hirafuji, M; Hiroshige, T; Machida, M; Minami, M; Ogata, A; Parvez, SH; Saito, H; Tashiro, K; Terado, M | 1 |
| Aráujo, DT; Cunha, GM; Maia, FD; Pitombeira, BS; Viana, GS | 1 |
| Bader, V; Foguet, M; Lübbert, H; Schoenebeck, B; Siebertz, B; Stichel, CC; Zhu, XR | 1 |
| Alper, G; Caglayan, O; Duman, E; Irer, S; Yilmaz, C | 1 |
| Mohanakumar, KP; Saravanan, KS; Senthilkumar, KS; Sindhu, KM | 1 |
| Jyoti, A; Sethi, P; Sharma, D | 1 |
| Alper, GE; Duman, E; Irer, SV; Saatcioglu, F; Sezer, ED; Yilmaz, C | 1 |
| Toronyi, E | 1 |
| Mouri, A; Nabeshima, T; Noda, Y; Tsunekawa, H; Yoneda, F | 1 |
| Hönack, D; Löscher, W | 1 |
| Adeyemo, OM; Markey, CJ; Markey, SP; Pollard, HB; Youdim, MB | 1 |
| Stern, G | 1 |
| Barthalmus, GT; Hardin, LK; Thompson, D | 1 |
| Arányi, P; Gaál, J; Kardos, V; Király, I; Kollár, E; Patthy, M; Sziráki, I; Tömösközi, Z | 1 |
| Bruyette, DS; Ruehl, WW; Smidberg, TL | 1 |
| Bruyette, DS; Cotman, CW; Cummings, BJ; DePaoli, A; Head, E; Milgram, NW; Ruehl, WW | 1 |
| Butterworth, RF; Todd, KG | 1 |
| Bernardi, G; Bonci, A; Federici, M; Mercuri, NB; Scarponi, M; Siniscalchi, A | 1 |
| Boix, F; Kolpus, T; Qiao, SW; Sagvolden, T | 1 |
| Cathcart, S; Sachdev, P; Saharov, T | 1 |
| Dong, E; Kawai, H; Liang, CS; Shite, J; Stevens, SY | 1 |
| Hamm, RJ; Phillips, LL; Povlishock, JT; Reeves, TM; Zhu, J | 1 |
| Hengerer, B; Spooren, WP; Waldmeier, PC | 1 |
| Haapalinna, A; Jolkkonen, J; Puurunen, K; Sirviö, J; Sivenius, J | 1 |
| Boulton, AA; Cools, AR; Kato, AC; Tatton, WG; Waldmeier, PC | 1 |
| Morón, J; Pastó, M; Pérez, V; Unzeta, M | 1 |
| Chen, RC; Chen, TH; Liou, HH; Tsai, MC; Tsai, YF | 1 |
| Czub, M; Czub, S; Gerlach, M; Gosztonyi, G; Gsell, W; Heeney, JL; Koutsilieri, E; Müller, JG; Pedersen, V; Riederer, P; Sopper, S; Stahl-Hennig, C; ter Meulen, V | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Castagnoli, K; Castagnoli, N; Steyn, SJ | 1 |
| Breithaupt, W; Gerlach, M; Götz, ME; Kupsch, A; Oertel, WH; Riederer, P; Sautter, J; Schwarz, J; Youdim, MB | 1 |
| Asari, S; Goldstein, M; Nakashima, H; Nishimoto, A | 1 |
| Chen, S | 1 |
| Jenner, P; Marsden, CD | 1 |
| Sheng, JG; Xu, DL; Yu, HZ | 1 |
6 review(s) available for selegiline and Disease Models, Animal
| Article | Year |
|---|---|
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Disease Models, Animal; Humans; Indans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Protein Structure, Quaternary; Selegiline | 2010 |
[Role of apoptosis in the kidney after reperfusion].
Topics: Animals; Apoptosis; Bepridil; Calcium Channel Blockers; Disease Models, Animal; Fendiline; Humans; Kidney Transplantation; Kidney Tubules; Monoamine Oxidase Inhibitors; Nifedipine; Reperfusion Injury; Selegiline; Vasodilator Agents; Verapamil | 2008 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with 1-deprenyl.
Topics: Adrenocortical Hyperfunction; Animals; Disease Models, Animal; Dogs; Dopamine; Nerve Degeneration; Pituitary Gland; Selegiline | 1995 |
Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy.
Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Dementia; Disease Models, Animal; Dogs; Humans; Selegiline | 1995 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
1 trial(s) available for selegiline and Disease Models, Animal
| Article | Year |
|---|---|
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
63 other study(ies) available for selegiline and Disease Models, Animal
| Article | Year |
|---|---|
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Female; Male; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Quinoxalines; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Neuroprotective effect of paeoniflorin in the mouse model of Parkinson's disease through α-synuclein/protein kinase C δ subtype signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Glucosides; Mice; Microscopy, Electron, Transmission; Monoterpenes; Neurotoxins; Parkinsonian Disorders; Protein Kinase C-delta; Rotarod Performance Test; Selegiline; Substantia Nigra | 2021 |
Effect of selegiline as a monomine oxidase B inhibitor on the expression of neurotrophin mRNA levels in a contusion rat model of spinal cord injury.
Topics: Animals; Contusions; Disease Models, Animal; Nerve Growth Factors; Oxidoreductases; Rats; Rats, Sprague-Dawley; Recovery of Function; RNA, Messenger; Selegiline; Spinal Cord; Spinal Cord Injuries | 2023 |
The novel design of an intelligent anti-depression transdermal drug delivery system.
Topics: Administration, Cutaneous; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Delivery Systems; Hippocampus; Humans; Rats; Selegiline | 2023 |
Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response.
Topics: Animals; Anxiety; Behavior, Animal; Benzofurans; Corticosterone; Disease Models, Animal; Drug Synergism; Glutamic Acid; Male; Maze Learning; Neurotransmitter Agents; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Selegiline; Stress, Psychological | 2020 |
Blocking Astrocytic GABA Restores Synaptic Plasticity in Prefrontal Cortex of Rat Model of Depression.
Topics: Animals; Astrocytes; Atrophy; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Long-Term Potentiation; Male; Neuronal Plasticity; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, GABA; Selegiline | 2020 |
Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice.
Topics: Administration, Oral; Aging; Animals; Antiparkinson Agents; Auditory Threshold; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Hearing Loss, Sensorineural; Humans; Male; Mice, Inbred BALB C; Mice, Inbred DBA; Protective Agents; Selegiline; Synaptic Transmission | 2021 |
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Death; Dendritic Spines; Dihydroxyphenylalanine; Disease Models, Animal; Dopaminergic Neurons; Food; Hippocampus; Inflammation; Memory; Mice, Transgenic; Nerve Degeneration; Neuronal Plasticity; Nucleus Accumbens; Plaque, Amyloid; Reward; Selegiline; Ventral Tegmental Area | 2017 |
Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.
Topics: Animals; Antioxidants; Apoptosis; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Glutathione; Lipid Peroxidation; Male; Neuroprotective Agents; Nitro Compounds; Prepulse Inhibition; Propionates; Rats; Rats, Wistar; Selegiline | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Monoamine oxidase-B inhibitor protects degenerating spinal neurons, enhances nerve regeneration and functional recovery in sciatic nerve crush injury model.
Topics: Animals; Anterior Horn Cells; Disease Models, Animal; Gene Expression Regulation; Male; Monoamine Oxidase Inhibitors; Movement; Myelin Basic Protein; Nerve Degeneration; Nerve Fibers, Myelinated; Nerve Regeneration; Pain Threshold; Phosphopyruvate Hydratase; Rats; Rats, Wistar; Recovery of Function; Sciatic Neuropathy; Selegiline; Spinal Cord; Weight-Bearing | 2018 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Compounding; Haloperidol; Male; Nanoparticles; Oxidative Stress; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Up-Regulation | 2018 |
Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Behavior, Animal; Biological Availability; Brain; Chitosan; Disease Models, Animal; Drug Carriers; Drug Liberation; Male; Nanoparticles; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Tissue Distribution | 2018 |
Adjuvant potential of selegiline in treating acute toxicity of aluminium phosphide in rats.
Topics: Aluminum Compounds; Animals; Antidotes; Disease Models, Animal; Drug Evaluation, Preclinical; Duodenum; Heart; Humans; Injections, Intraperitoneal; Male; Membrane Potential, Mitochondrial; Mitochondria; Myocardium; Oxidative Stress; Pesticides; Phosphines; Poisoning; Rats; Reactive Oxygen Species; Selegiline; Stomach; Treatment Outcome | 2019 |
Prevention of Mammary Tumor Development through Neuroimmunomodulation in the Spleen and Lymph Nodes of Old Female Sprague-Dawley Rats by L-Deprenyl.
Topics: Age Factors; Analysis of Variance; Animals; Breast Neoplasms; Cell Proliferation; Concanavalin A; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Killer Cells, Natural; Lymph Nodes; Neoplasm Transplantation; Neuroimmunomodulation; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Selegiline; Spleen | 2013 |
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Disease Models, Animal; Dopaminergic Neurons; Gait; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Real-Time Polymerase Chain Reaction; RNA, Messenger; Selegiline | 2013 |
Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Selegiline | 2013 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2015 |
Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis.
Topics: Acidosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arterial Pressure; Caspase 3; Disease Models, Animal; Drug Repositioning; Injections, Intravenous; Interleukin-6; Kidney; Liver; Lung; Male; Neuroprotective Agents; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Peritonitis; Rats; Rats, Wistar; Selegiline; Sepsis; Superoxides; Survival Analysis | 2014 |
Selegiline promotes NOTCH-JAGGED signaling in astrocytes of the peri-infarct region and improves the functional integrity of the neurovascular unit in a rat model of focal ischemia.
Topics: Animals; Astrocytes; bcl-X Protein; Brain Edema; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; Drug Delivery Systems; Gene Expression Regulation; Infarction, Middle Cerebral Artery; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Male; Membrane Proteins; Neuroprotective Agents; Rats; Rec A Recombinases; Receptors, Notch; Recovery of Function; Selegiline; Serrate-Jagged Proteins; Signal Transduction; Time Factors; Transcriptome; X-Linked Inhibitor of Apoptosis Protein | 2015 |
Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Chitosan; Depression; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Nanoparticles; Rats; Rats, Wistar; Selegiline | 2016 |
Autophagy-related protein expression in the substantia nigra and eldepryl intervention in rat models of Parkinson's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Beclin-1; Disease Models, Animal; Insecticides; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline; Substantia Nigra; Time Factors | 2015 |
Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Food Preferences; Grooming; Male; Maternal Deprivation; Mice; Motivation; Receptors, Dopamine D1; Receptors, Dopamine D2; Selegiline; Swimming | 2016 |
Rats bred for helplessness exhibit positive reinforcement learning deficits which are not alleviated by an antidepressant dose of the MAO-B inhibitor deprenyl.
Topics: Animals; Antidepressive Agents; Appetite; Conditioning, Operant; Depressive Disorder; Disease Models, Animal; Extinction, Psychological; Helplessness, Learned; Learning Disabilities; Male; Monoamine Oxidase Inhibitors; Motivation; Motor Activity; Nootropic Agents; Rats, Sprague-Dawley; Reinforcement, Psychology; Resilience, Psychological; Selegiline; Species Specificity | 2016 |
Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; CD11b Antigen; Cell Proliferation; Corpus Striatum; Disease Models, Animal; Glial Fibrillary Acidic Protein; Male; Neuroglia; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra; Time Factors | 2017 |
Neuroprotection by rasagiline in thiamine deficient rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Indans; Kaplan-Meier Estimate; Male; Maze Learning; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Thiamine Deficiency | 2009 |
The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.
Topics: Adiposity; Animals; Disease Models, Animal; Fatty Liver; Free Radical Scavengers; Luminescent Measurements; Male; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Selegiline; Time Factors | 2012 |
Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice.
Topics: Animals; Clorgyline; Disease Models, Animal; Female; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuralgia; Postoperative Complications; Rotarod Performance Test; Selegiline | 2012 |
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease Models, Animal; Ditiocarb; Dopamine; Down-Regulation; Drug Synergism; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Presynaptic Terminals; Selegiline; Substantia Nigra | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin | 2003 |
Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Topics: Animals; Disease Models, Animal; Dopamine; Encephalitis Virus, Japanese; Hypokinesia; Isatin; Mice; Monoamine Oxidase Inhibitors; Parkinson Disease; Rats; Selegiline | 2004 |
l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats.
Topics: Animals; Antioxidants; Avoidance Learning; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Lipid Peroxidation; Maze Learning; Memory Disorders; Motor Activity; Neuroprotective Agents; Nitrites; Rats; Rats, Wistar; Selegiline; Thiobarbituric Acid Reactive Substances | 2004 |
sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Astrocytes; Blotting, Northern; Brain; Cell Death; Cluster Analysis; Disease Models, Animal; Drug Interactions; Food Deprivation; Gene Expression; Gene Expression Profiling; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Immediate-Early Proteins; In Situ Hybridization; Mice; Neurons; Nuclear Proteins; Parkinsonian Disorders; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selegiline; Time Factors; Tyrosine 3-Monooxygenase; Water Deprivation | 2005 |
Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aging; Animals; Antioxidants; Blood Glucose; Body Weight; Deoxyguanosine; Diabetes Mellitus, Experimental; Disease Models, Animal; DNA Damage; Gliclazide; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidants; Oxidative Stress; Rats; Rats, Inbred Strains; Selegiline; Superoxide Dismutase; Vitamin A; Vitamin E | 2005 |
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Topics: Amphetamine; Animals; Catalase; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Electron Transport Complex I; Hydroxyl Radical; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2006 |
Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain.
Topics: Aldehydes; Aluminum Chloride; Aluminum Compounds; Animals; Antioxidants; Bacopa; Cerebral Cortex; Chlorides; Disease Models, Animal; Glutathione; Glutathione Peroxidase; Glutathione Transferase; India; Lipid Peroxidation; Male; Medicine, Ayurvedic; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidative Stress; Plant Extracts; Protein Carbonylation; Rats; Rats, Wistar; Selegiline; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2007 |
The effect of l-deprenyl on tissue mRNA expressions of NOS isoforms and NO levels in an experimental diabetes mellitus model.
Topics: Aging; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Heart; Isoenzymes; Liver; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; RNA, Messenger; Selegiline; Treatment Outcome | 2007 |
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Association Learning; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indans; Male; Maze Learning; Mice; Mice, Inbred ICR; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Piperidines; Recognition, Psychology; Selegiline; Single-Blind Method; Statistics, Nonparametric | 2008 |
Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Female; Humans; Kindling, Neurologic; Rats; Rats, Wistar; Selegiline | 1995 |
L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Dopamine; Goldfish; Monoamine Oxidase; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease, Secondary; Selegiline | 1993 |
MAO-A and -B inhibitors selectively alter Xenopus mucus-induced behaviors of snakes.
Topics: Analysis of Variance; Animals; Behavior, Animal; Clorgyline; Disease Models, Animal; Movement Disorders; Mucus; Selegiline; Snakes; Xenopus laevis | 1993 |
Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Time Factors | 1995 |
Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency.
Topics: Animals; Behavior, Animal; Cell Count; Cell Survival; Disease Models, Animal; Drug Administration Schedule; Immunohistochemistry; Injections, Intraperitoneal; Male; Monoamine Oxidase Inhibitors; Neurons; Pyrithiamine; Rats; Rats, Sprague-Dawley; Selegiline; Thiamine Deficiency | 1998 |
Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Electrophysiology; Injections, Intraperitoneal; Levodopa; Male; Membrane Potentials; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Wistar; Selegiline | 1998 |
Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder.
Topics: Animals; Appetitive Behavior; Attention Deficit Disorder with Hyperactivity; Brain; Disease Models, Animal; Dopamine; Impulsive Behavior; Male; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reinforcement Schedule; Selegiline; Serotonin; Species Specificity | 1998 |
The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Delayed-Action Preparations; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluphenazine; Free Radicals; Male; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Vitamin E | 1999 |
Selegiline improves cardiac sympathetic terminal function and beta-adrenergic responsiveness in heart failure.
Topics: Analysis of Variance; Animals; Baroreflex; Binding Sites; Cardiac Pacing, Artificial; Disease Models, Animal; Echocardiography; Heart; Heart Failure; Immunohistochemistry; Isoproterenol; Neuroprotective Agents; Norepinephrine; Rabbits; Receptors, Adrenergic, beta; Selegiline; Sympathetic Nervous System; Sympatholytics | 2000 |
Postinjury administration of L-deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury.
Topics: Acetylcholinesterase; Animals; Axons; Brain Injuries; Cognition; Cognition Disorders; Disease Models, Animal; Dopamine beta-Hydroxylase; Entorhinal Cortex; Hippocampus; Male; Maze Learning; Motor Activity; Neural Pathways; Neuronal Plasticity; Rats; Rats, Sprague-Dawley; Recovery of Function; Selegiline; Time Factors | 2000 |
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase | 2000 |
Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats.
Topics: Animals; Behavior, Animal; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Environment; Forelimb; Housing, Animal; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Selegiline; Spatial Behavior | 2001 |
Neurorescuing effects of the GAPDH ligand CGP 3466B.
Topics: Animals; Animals, Newborn; Brain; Cell Survival; Cells, Cultured; Disease Models, Animal; Glyceraldehyde-3-Phosphate Dehydrogenases; Ligands; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Oxepins; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 2000 |
Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Indoles; Male; Methylamines; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Selegiline | 2000 |
Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo.
Topics: Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Herbicides; Male; Neuroprotective Agents; Paraquat; Rats; Rats, Wistar; Selegiline; Stereotyped Behavior; Substantia Nigra | 2001 |
Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs.
Topics: AIDS Dementia Complex; Animals; Central Nervous System; Dendrites; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Encephalitis, Viral; Macaca mulatta; Neuroprotective Agents; Selegiline; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Time Factors; Vacuoles; Virus Replication | 2001 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine.
Topics: Animals; Antiparkinson Agents; Cell Death; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinsonian Disorders; Selegiline | 2001 |
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Immunohistochemistry; Indans; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Neostriatum; Neurons; Norepinephrine; Parkinsonian Disorders; Selegiline; Serotonin; Substantia Nigra | 2001 |
[The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Rotation; Selegiline | 1991 |
[Study of an MPTP-induced parkinsonian animal model in the rhesus monkey and the mechanism of the action of MPTP].
Topics: Animals; Disease Models, Animal; Macaca mulatta; Male; MPTP Poisoning; MSH Release-Inhibiting Hormone; Parkinson Disease, Secondary; Selegiline | 1990 |
L-deprenyl in prevention of MPTP induced depletion of striatal enkephalins in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Enkephalin, Leucine; Enkephalin, Methionine; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism | 1988 |